Zoetis (ZTS) Cash from Investing Activities (2012 - 2026)
Zoetis' (ZTS) quarterly Cash from Investing Activities came in at -$87.0 million in Q1 2026, up 57.14% year-on-year from -$55.4 million in Q1 2025, and up 47.59% on a QoQ basis from -$166.0 million in Q4 2025.
Zoetis (ZTS) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Cash from Investing Activities data on file, last reported at -$87.0 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 57.14% year-over-year to -$87.0 million in Q1 2026; TTM through Mar 2026 was -$632.0 million, a 63.31% decrease from a year earlier, with the FY2025 full-year figure at -$748.0 million, down 137.46% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$87.0 million, up from -$166.0 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for ZTS reached as high as $126.0 million in Q4 2024 and fell as low as -$438.0 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$165.3 million across 5 years, with a median of -$166.0 million in 2025.
- Across the five-year window, Cash from Investing Activities jumped 160.0% in 2024 and tumbled 231.75% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at -$438.0 million in 2022, then surged by 52.05% to -$210.0 million in 2023, then soared by 160.0% to $126.0 million in 2024, then tumbled by 231.75% to -$166.0 million in 2025, then jumped by 47.59% to -$87.0 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$87.0 million in Q1 2026, -$166.0 million in Q4 2025, and -$160.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.00 Mn |
| Mar 31, 2026 | -87.00 Mn |
| Dec 31, 2025 | -166.00 Mn |
| Dec 31, 2025 | -166.00 Mn |
| Sep 30, 2025 | -160.00 Mn |
| Sep 30, 2025 | -160.00 Mn |
| Jun 30, 2025 | -219.00 Mn |
| Jun 30, 2025 | -219.00 Mn |
| Mar 31, 2025 | -203.00 Mn |
| Mar 31, 2025 | -203.00 Mn |
| Dec 31, 2024 | 126.00 Mn |
| Dec 31, 2024 | 126.00 Mn |
| Sep 30, 2024 | -178.00 Mn |
| Sep 30, 2024 | -178.00 Mn |
| Jun 30, 2024 | -132.00 Mn |
| Jun 30, 2024 | -132.00 Mn |
| Mar 31, 2024 | -131.00 Mn |
| Mar 31, 2024 | -131.00 Mn |
| Dec 31, 2023 | -210.00 Mn |
| Dec 31, 2023 | -210.00 Mn |